# AC Immune to Present at the Jefferies 2025 London Healthcare Conference Canonical URL: https://biopharmsignal.com/news/ACIU/ac-immune-to-present-at-the-jefferies-2025-london-healthcare-conference-a3e7244f Ticker: ACIU Company: AC Immune Source: AC Immune Published: 2025-11-11 12:00 EST ## Summary AC Immune to Present at the Jefferies 2025 London Healthcare Conference Lausanne, Switzerland, November 11, 2025 -- AC Immune SA (NASDAQ: ACIU), a... ## Article Body AC Immune to Present at the Jefferies 2025 London Healthcare Conference Lausanne, Switzerland, November 11, 2025 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced that Company Management will participate in a fireside chat and one-on-one investor meetings during the Jefferies Global Healthcare Conference in London, taking place November 17-20, 2025. The fireside chat will take place on November 18, 2025, at 4:30 AM (ET) / 9:30 AM (GMT). A webcast of the fireside chat will be available on the Events Page of AC Immune’s website. A replay will be archived in the same location. Please contact your Jefferies representative to request a meeting with AC Immune’s management team at the conference. About AC Immune SA AC Immune SA is a clinical-stage biopharmaceutical company and a global leader in precision prevention for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen® and Morphomer®, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features a range of therapeutic and diagnostic programs, including candidates in Phase 2 and Phase 3 development. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies, resulting in substantial non-dilutive funding to advance its proprietary programs and >$4.5 billion in potential milestone payments plus royalties. SupraAntigen® is a registered trademark of AC Immune SA in the following territories: AU, EU, CH, GB, JP, RU, SG and USA. Morphomer® is a registered trademark of AC Immune SA in CN, CH, EU, GB, JP, KR, NO, RU and SG. The information on our website and any other websites referenced herein is expressly not incorporated by reference into, and does not constitute a part of, this press release. For further information, please contact: Forward looking statements This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement. 20251110__ACIU Jefferies presentation_FINAL ## Recent Company News - 2026-07-07 11:00 EST — [AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC® 2026](https://biopharmsignal.com/news/ACIU/ac-immune-to-showcase-neurodegenerative-disease-pipeline-with-three-presentation-edc83995) — Source: AC Immune - 2026-06-30 11:00 EST — [AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer’s Disease](https://biopharmsignal.com/news/ACIU/ac-immune-reports-interim-12-month-data-from-phase-1b-2-abate-trial-of-aci-24-in-aa4acde5) — Source: AC Immune - 2026-06-11 11:00 EST — [AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson’s Disease](https://biopharmsignal.com/news/ACIU/ac-immune-to-receive-research-grant-from-goradia-family-for-development-of-aci-7-f87fb9a8) — Source: AC Immune - 2026-05-22 11:00 EST — [AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS](https://biopharmsignal.com/news/ACIU/ac-immune-presents-new-phase-1-data-indicating-higher-uptake-of-tdp-43-pet-trace-219b543b) — Source: AC Immune - 2026-05-12 11:00 EST — [AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM](https://biopharmsignal.com/news/ACIU/ac-immune-announces-retirement-of-ceo-dr-andrea-pfeifer-at-upcoming-agm-b1180180) — Source: AC Immune ## Related News - 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9) - 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627) - 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922) - 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c) - 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)